Antivirals given for chronic hepatitis B include nucleos(t)ide analog monotherapy and pegylated interferon-alpha therapy, but ...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at ...
Patients in the Phase 3 MAESTRO-NAFLD-1 trial achieved a statistically significant mean reduction of 6.7 kPa in liver stiffness, the largest reported in compensated MASH cirrhosis populations. 51% of ...
Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) after 36 ...
Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over ...
Cirrhosis is categorized into two distinct stages: compensated and decompensated. In the compensated stage, despite presence of considerable damage, the liver maintains sufficient residual function to ...
The last time I wrote about Akero Therapeutics (AKRO) it was with respect to a Seeking Alpha article entitled as "Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program". In this article, ...
A new study published in the journal of JHEP Reports revealed that regular dental prophylaxis and at least annual periodontal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results